

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

**NOTIFICATION OF A CIVIL SUIT FILED BY
A JOINT VENTURE PARTNER OF AN INDIRECT SUBSIDIARY**

The Board of Directors of Clearbridge Health Limited (the "**Company**") and together with its subsidiaries, the "**Group**") wishes to announce it has been made aware of a civil suit (the "**Suit**") filed by PT Tirta Medika Nusantara ("**TMN**"), an existing shareholder of an indirect subsidiary, PT Tirta Medika Jaya ("**TMJ**"), against, among others, (1) Clearbridge Medical Asia Pte. Ltd., a wholly-owned subsidiary of the Company ("**CBMA**"), and (2) TMJ.

By way of a letter dated 22 May 2020 (the "**Letter**") from TMN received via electronic mail by certain members of the Board of Directors and Board of Commissioners of TMJ on 25 May 2020, TMN informed TMJ that it had filed the Suit at the North Jakarta District Court (the "**Court**"), without naming the parties to the claim and stating the basis of its claim.

The Group has been advised by Indonesian legal counsel that under Indonesian law, the court bailiff will serve a formal written summons, which will include a copy of the claim, on the defendants to appear before the Court. In respect of CBMA, the formal written summons would be served through the Ministry of Foreign Affairs. As of the date of this announcement, neither TMJ nor CBMA has received any formal letter of demand from TMN relating to the claim or any written summons from the Court or other authorities. As a result, TMJ and CBMA are not able to ascertain the basis of TMN's claim.

Based on the information available from a case search on the Court's case tracking information system, it would appear that the Suit was filed on 6 May 2020 and TMN is seeking, among others, (a) the Court's declaration that a certain notarial deed has been made unlawfully and consequently (b) damages of IDR 1.06 trillion (approximately SGD 102 million). No substantiation has been provided by TMN on how this claim for IDR 1.06 trillion has been derived. The hearing before the Court has been scheduled to be held on 11 November 2020.

CMBA and TMJ are of the opinion that the notarial deed is in accordance with Indonesian law and there is no merit to the claim that it is unlawful. TMJ has engaged Indonesian legal counsel and the Company will continue to update its shareholders if there are any material developments on this matter. In the meantime, the operations at TMJ are unaffected by this event.

Shareholders and potential investors should note that as the basis of TMN's claim is presently unclear to the Group, shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

YEE PINH JEREMY

Executive Director and Chief Executive Officer

31 May 2020

This announcement has been prepared by Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.